Vertex Pharmaceuticals Inc (VRTX)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		6.27	6.24	6.07	5.91	6.15	6.23	6.21	6.09	6.60	6.42	7.13	6.50	6.94	7.49	6.75	5.64	6.48	8.07	7.35	7.37
DSO	days	58.21	58.52	60.14	61.78	59.39	58.59	58.78	59.93	55.33	56.83	51.21	56.14	52.57	48.70	54.04	64.77	56.32	45.23	49.67	49.50

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 6.27
= 58.21

To analyze Vertex Pharmaceuticals, Inc.'s days of sales outstanding (DSO) trend, we observed a gradual increase in DSO over the past eight quarters. In Q4 2023, the DSO stood at 57.82 days, which was slightly lower than the previous quarter at 58.17 days. Despite this minor decrease, the trend still reflects an upward trajectory compared to previous quarters. Overall, the company's collection period has lengthened over time, indicating a potential delay in collecting its accounts receivable. This trend suggests a need for Vertex Pharmaceuticals, Inc. to focus on improving its accounts receivable management and collection processes to ensure timely revenue collection and cash flow optimization.